1 Report Overview

• 1.1 Study Scope
• 1.2 Key Market Segments
• 1.3 Players Covered: Ranking by IBS-C Drugs Revenue
• 1.4 Market by Type
  • 1.4.1 Global IBS-C Drugs Market Size Growth Rate by Type: 2020 VS 2026
  • 1.4.2 Linaclotide
  • 1.4.3 Lubiprostone
  • 1.4.4 Osmotic Laxatives
  • 1.4.5 Stimulant Laxatives
  • 1.4.6 Other
• 1.5 Market by Application
  • 1.5.1 Global IBS-C Drugs Market Share by Application: 2020 VS 2026
  • 1.5.2 Hospital Pharmacies
  • 1.5.3 Retail Pharmacies
  • 1.5.4 Online Pharmacies
• 1.6 Study Objectives
• 1.7 Years Considered

2 Global Growth Trends

• 2.1 Global IBS-C Drugs Market Perspective (2015-2026)
• 2.2 Global IBS-C Drugs Growth Trends by Regions
  • 2.2.1 IBS-C Drugs Market Size by Regions: 2015 VS 2020 VS 2026
  • 2.2.2 IBS-C Drugs Historic Market Share by Regions (2015-2020)
  • 2.2.3 IBS-C Drugs Forecasted Market Size by Regions (2021-2026)
• 2.3 Industry Trends and Growth Strategy
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers
  • 2.3.3 Market Challenges
  • 2.3.4 Porter’s Five Forces Analysis
  • 2.3.5 IBS-C Drugs Market Growth Strategy
  • 2.3.6 Primary Interviews with Key IBS-C Drugs Players (Opinion Leaders)

3 Competition Landscape by Key Players

• 3.1 Global Top IBS-C Drugs Players by Market Size
  • 3.1.1 Global Top IBS-C Drugs Players by Revenue (2015-2020)
  • 3.1.2 Global IBS-C Drugs Revenue Market Share by Players (2015-2020)
  • 3.1.3 Global IBS-C Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
• 3.2 Global IBS-C Drugs Market Concentration Ratio
  • 3.2.1 Global IBS-C Drugs Market Concentration Ratio (CR5 and HHI)
  • 3.2.2 Global Top 10 and Top 5 Companies by IBS-C Drugs Revenue in 2019
• 3.3 IBS-C Drugs Key Players Head office and Area Served
• 3.4 Key Players IBS-C Drugs Product Solution and Service
• 3.5 Date of Enter into IBS-C Drugs Market
• 3.6 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)

• 4.1 Global IBS-C Drugs Historic Market Size by Type (2015-2020)
• 4.2 Global IBS-C Drugs Forecasted Market Size by Type (2021-2026)

5 Market Size by Application (2015-2026)

• 5.1 Global IBS-C Drugs Market Size by Application (2015-2020)
• 5.2 Global IBS-C Drugs Forecasted Market Size by Application (2021-2026)

6 North America

• 6.1 North America IBS-C Drugs Market Size (2015-2020)
• 6.2 IBS-C Drugs Key Players in North America (2019-2020)
• 6.3 North America IBS-C Drugs Market Size by Type (2015-2020)
• 6.4 North America IBS-C Drugs Market Size by Application (2015-2020)

7 Europe

• 7.1 Europe IBS-C Drugs Market Size (2015-2020)
• 7.2 IBS-C Drugs Key Players in Europe (2019-2020)
• 7.3 Europe IBS-C Drugs Market Size by Type (2015-2020)
• 7.4 Europe IBS-C Drugs Market Size by Application (2015-2020)

8 China

• 8.1 China IBS-C Drugs Market Size (2015-2020)
• 8.2 IBS-C Drugs Key Players in China (2019-2020)
• 8.3 China IBS-C Drugs Market Size by Type (2015-2020)
• 8.4 China IBS-C Drugs Market Size by Application (2015-2020)

9 Japan

• 9.1 Japan IBS-C Drugs Market Size (2015-2020)
• 9.2 IBS-C Drugs Key Players in Japan (2019-2020)
• 9.3 Japan IBS-C Drugs Market Size by Type (2015-2020)
• 9.4 Japan IBS-C Drugs Market Size by Application (2015-2020)

10 Southeast Asia

• 10.1 Southeast Asia IBS-C Drugs Market Size (2015-2020)
• 10.2 IBS-C Drugs Key Players in Southeast Asia (2019-2020)
• 10.3 Southeast Asia IBS-C Drugs Market Size by Type (2015-2020)
• 10.4 Southeast Asia IBS-C Drugs Market Size by Application (2015-2020)

11 India

• 11.1 India IBS-C Drugs Market Size (2015-2020)
• 11.2 IBS-C Drugs Key Players in India (2019-2020)
• 11.3 India IBS-C Drugs Market Size by Type (2015-2020)
• 11.4 India IBS-C Drugs Market Size by Application (2015-2020)

12 Central & South America

• 12.1 Central & South America IBS-C Drugs Market Size (2015-2020)
• 12.2 IBS-C Drugs Key Players in Central & South America (2019-2020)
• 12.3 Central & South America IBS-C Drugs Market Size by Type (2015-2020)
• 12.4 Central & South America IBS-C Drugs Market Size by Application (2015-2020)

13 Key Players Profiles

• 13.1 Catalent Pharmaceuticals Solutions
  • 13.1.1 Catalent Pharmaceuticals Solutions Company Details
  • 13.1.2 Catalent Pharmaceuticals Solutions Business Overview
  • 13.1.3 Catalent Pharmaceuticals Solutions IBS-C Drugs Introduction
  • 13.1.4 Catalent Pharmaceuticals Solutions Revenue in IBS-C Drugs Business (2015-2020))
  • 13.1.5 Catalent Pharmaceuticals Solutions Recent Development
• 13.2 Nestle
  • 13.2.1 Nestle Company Details
  • 13.2.2 Nestle Business Overview
  • 13.2.3 Nestle IBS-C Drugs Introduction
  • 13.2.4 Nestle Revenue in IBS-C Drugs Business (2015-2020)
  • 13.2.5 Nestle Recent Development
• 13.3 Abbott Laboratories
  • 13.3.1 Abbott Laboratories Company Details
  • 13.3.2 Abbott Laboratories Business Overview
  • 13.3.3 Abbott Laboratories IBS-C Drugs Introduction
  • 13.3.4 Abbott Laboratories Revenue in IBS-C Drugs Business (2015-2020)
  • 13.3.5 Abbott Laboratories Recent Development
• 13.4 Synergy Pharmaceuticals
  • 13.4.1 Synergy Pharmaceuticals Company Details
  • 13.4.2 Synergy Pharmaceuticals Business Overview
  • 13.4.3 Synergy Pharmaceuticals IBS-C Drugs Introduction
  • 13.4.4 Synergy Pharmaceuticals Revenue in IBS-C Drugs Business (2015-2020)
  • 13.4.5 Synergy Pharmaceuticals Recent Development
• 13.5 Sucampo Pharmaceuticals
  • 13.5.1 Sucampo Pharmaceuticals Company Details
  • 13.5.2 Sucampo Pharmaceuticals Business Overview
  • 13.5.3 Sucampo Pharmaceuticals IBS-C Drugs Introduction
  • 13.5.4 Sucampo Pharmaceuticals Revenue in IBS-C Drugs Business (2015-2020)
  • 13.5.5 Sucampo Pharmaceuticals Recent Development
• 13.6 Novartis Pharma Ag
  • 13.6.1 Novartis Pharma Ag Company Details
  • 13.6.2 Novartis Pharma Ag Business Overview
  • 13.6.3 Novartis Pharma Ag IBS-C Drugs Introduction
  • 13.6.4 Novartis Pharma Ag Revenue in IBS-C Drugs Business (2015-2020)
  • 13.6.5 Novartis Pharma Ag Recent Development
• 13.7 Astellas Pharmaceuticals
  • 13.7.1 Astellas Pharmaceuticals Company Details
  • 13.7.2 Astellas Pharmaceuticals Business Overview
  • 13.7.3 Astellas Pharmaceuticals IBS-C Drugs Introduction
  • 13.7.4 Astellas Pharmaceuticals Revenue in IBS-C Drugs Business (2015-2020)
  • 13.7.5 Astellas Pharmaceuticals Recent Development
• 13.8 Ardelyx, Inc
  • 13.8.1 Ardelyx, Inc Company Details
  • 13.8.2 Ardelyx, Inc Business Overview
  • 13.8.3 Ardelyx, Inc IBS-C Drugs Introduction
  • 13.8.4 Ardelyx, Inc Revenue in IBS-C Drugs Business (2015-2020)
  • 13.8.5 Ardelyx, Inc Recent Development
• 13.9 Synthetic Biologics, Inc
  • 13.9.1 Synthetic Biologics, Inc Company Details
  • 13.9.2 Synthetic Biologics, Inc Business Overview
  • 13.9.3 Synthetic Biologics, Inc IBS-C Drugs Introduction
  • 13.9.4 Synthetic Biologics, Inc Revenue in IBS-C Drugs Business (2015-2020)
  • 13.9.5 Synthetic Biologics, Inc Recent Development
• 13.10 Teva Pharmaceutical Industries
  • 13.10.1 Teva Pharmaceutical Industries Company Details
  • 13.10.2 Teva Pharmaceutical Industries Business Overview
  • 13.10.3 Teva Pharmaceutical Industries IBS-C Drugs Introduction
  • 13.10.4 Teva Pharmaceutical Industries Revenue in IBS-C Drugs Business (2015-2020)
  • 13.10.5 Teva Pharmaceutical Industries Recent Development
• 13.11 Bama-Geve, SLU
  • 10.11.1 Bama-Geve, SLU Company Details
  • 10.11.2 Bama-Geve, SLU Business Overview
  • 10.11.3 Bama-Geve, SLU IBS-C Drugs Introduction
  • 10.11.4 Bama-Geve, SLU Revenue in IBS-C Drugs Business (2015-2020)
  • 10.11.5 Bama-Geve, SLU Recent Development
• 13.12 Ferring BV
  • 10.12.1 Ferring BV Company Details
  • 10.12.2 Ferring BV Business Overview
  • 10.12.3 Ferring BV IBS-C Drugs Introduction
  • 10.12.4 Ferring BV Revenue in IBS-C Drugs Business (2015-2020)
  • 10.12.5 Ferring BV Recent Development
• 13.13 Ironwood Pharmaceuticals, Inc
  • 10.13.1 Ironwood Pharmaceuticals, Inc Company Details
  • 10.13.2 Ironwood Pharmaceuticals, Inc Business Overview
  • 10.13.3 Ironwood Pharmaceuticals, Inc IBS-C Drugs Introduction
  • 10.13.4 Ironwood Pharmaceuticals, Inc Revenue in IBS-C Drugs Business (2015-2020)
  • 10.13.5 Ironwood Pharmaceuticals, Inc Recent Development
• 13.14 Salix Pharmaceuticals Ltd
  • 10.14.1 Salix Pharmaceuticals Ltd Company Details
  • 10.14.2 Salix Pharmaceuticals Ltd Business Overview
  • 10.14.3 Salix Pharmaceuticals Ltd IBS-C Drugs Introduction
  • 10.14.4 Salix Pharmaceuticals Ltd Revenue in IBS-C Drugs Business (2015-2020)
  • 10.14.5 Salix Pharmaceuticals Ltd Recent Development
• 13.15 Norgine B.V
  • 10.15.1 Norgine B.V Company Details
  • 10.15.2 Norgine B.V Business Overview
  • 10.15.3 Norgine B.V IBS-C Drugs Introduction
  • 10.15.4 Norgine B.V Revenue in IBS-C Drugs Business (2015-2020)
  • 10.15.5 Norgine B.V Recent Development
• 13.16 Prometheus Laboratories Inc
  • 10.16.1 Prometheus Laboratories Inc Company Details
  • 10.16.2 Prometheus Laboratories Inc Business Overview
  • 10.16.3 Prometheus Laboratories Inc IBS-C Drugs Introduction
  • 10.16.4 Prometheus Laboratories Inc Revenue in IBS-C Drugs Business (2015-2020)
  • 10.16.5 Prometheus Laboratories Inc Recent Development
• 13.17 Actavis Nordic A/S
  • 10.17.1 Actavis Nordic A/S Company Details
  • 10.17.2 Actavis Nordic A/S Business Overview
  • 10.17.3 Actavis Nordic A/S IBS-C Drugs Introduction
  • 10.17.4 Actavis Nordic A/S Revenue in IBS-C Drugs Business (2015-2020)
  • 10.17.5 Actavis Nordic A/S Recent Development
• 13.18 Albireo Pharma Inc
  • 10.18.1 Albireo Pharma Inc Company Details
  • 10.18.2 Albireo Pharma Inc Business Overview
  • 10.18.3 Albireo Pharma Inc IBS-C Drugs Introduction
  • 10.18.4 Albireo Pharma Inc Revenue in IBS-C Drugs Business (2015-2020)
  • 10.18.5 Albireo Pharma Inc Recent Development
• 13.19 Yuhan Corp
  • 10.19.1 Yuhan Corp Company Details
  • 10.19.2 Yuhan Corp Business Overview
  • 10.19.3 Yuhan Corp IBS-C Drugs Introduction
  • 10.19.4 Yuhan Corp Revenue in IBS-C Drugs Business (2015-2020)
  • 10.19.5 Yuhan Corp Recent Development
• 13.20 Astrazeneca Plc
  • 10.20.1 Astrazeneca Plc Company Details
  • 10.20.2 Astrazeneca Plc Business Overview
  • 10.20.3 Astrazeneca Plc IBS-C Drugs Introduction
  • 10.20.4 Astrazeneca Plc Revenue in IBS-C Drugs Business (2015-2020)
  • 10.20.5 Astrazeneca Plc Recent Development
• 13.21 The Menarini Group
  • 10.21.1 The Menarini Group Company Details
  • 10.21.2 The Menarini Group Business Overview
  • 10.21.3 The Menarini Group IBS-C Drugs Introduction
  • 10.21.4 The Menarini Group Revenue in IBS-C Drugs Business (2015-2020)
  • 10.21.5 The Menarini Group Recent Development
• 13.22 Ono Pharmaceutical Co., Ltd
  • 10.22.1 Ono Pharmaceutical Co., Ltd Company Details
  • 10.22.2 Ono Pharmaceutical Co., Ltd Business Overview
  • 10.22.3 Ono Pharmaceutical Co., Ltd IBS-C Drugs Introduction
  • 10.22.4 Ono Pharmaceutical Co., Ltd Revenue in IBS-C Drugs Business (2015-2020)
  • 10.22.5 Ono Pharmaceutical Co., Ltd Recent Development

14 Analyst's Viewpoints/Conclusions

15 Appendix

• 15.1 Research Methodology
  • 15.1.1 Methodology/Research Approach
  • 15.1.2 Data Source
• 15.2 Disclaimer

IBS-C Drugs market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global IBS-C Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

The key players covered in this study
Catalent Pharmaceuticals Solutions
Nestle
Abbott Laboratories
Synergy Pharmaceuticals
Sucampo Pharmaceuticals
Novartis Pharma Ag
Astellas Pharmaceuticals
Ardelyx, Inc
Synthetic Biologics, Inc
Teva Pharmaceutical Industries
Bama-Geve, SLU
Ferring BV
Ironwood Pharmaceuticals, Inc
Salix Pharmaceuticals Ltd
Norgine B.V
Prometheus Laboratories Inc
Actavis Nordic A/S
Albireo Pharma Inc
Yuhan Corp
Astrazeneca Plc
The Menarini Group
Ono Pharmaceutical Co., Ltd

Market segment by Type, the product can be split into
Linaclotide
Lubiprostone
Osmotic Laxatives
Stimulant Laxatives
Other
Market segment by Application, split into
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
Central & South America